Pharmaceutical Juno-B (02126) rose more than 8%. As of press release, it had risen 8.29% to HK$2.35, with a turnover of HK$2,041,800.
The Zhitong Finance App learned that Pharmaceutical Junuo B (02126) rose more than 8%. As of press release, it had risen 8.29% to HK$2.35, with a turnover of HK$2.041,800.
According to the news, Pharmaceutical Mingjunuo issued an announcement stating that the company announced the latest clinical data on patients with active systemic lupus erythematosus (SLE) in Chinese adults with active systemic lupus erythematosus (SLE) at the 2024 European Congress of Rheumatology (EULAR 2024). Preliminary data from the study showed that rekiolense injections can achieve deep and long-lasting disease relief in patients with moderate to severe lupus erythematosus, and are safe.
CICC previously pointed out that there is a high demand for treatment of moderate to severe SLE. The company's CAR-T products are the first in the world to expand into the field of chronic SLE diseases, and are expected to innovate patient treatment methods in the field of self-prevention, thereby expanding the market space for CAR-T therapy.